Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

C1orf190 Inhibitors

Chemical inhibitors of C1orf190 include a variety of compounds that interfere with kinase signaling pathways, which are crucial for the protein's function. Staurosporine serves as a broad-spectrum kinase inhibitor, which can target kinases responsible for the phosphorylation of C1orf190, thereby preventing its activation. Similarly, wortmannin and LY294002 are both inhibitors of PI3K, a kinase that can be upstream in the signaling cascade that activates C1orf190. By inhibiting PI3K, these chemicals can halt the activation process of C1orf190. Rapamycin, an mTOR inhibitor, is another agent that can interfere with signaling cascades involving C1orf190, as mTOR is often central to pathways that lead to protein activation. U0126 and PD98059 are inhibitors of MEK1/2, and by preventing MEK activation, the ERK pathway, which may regulate C1orf190, is inhibited. SB203580, a p38 MAP kinase inhibitor, can interfere with the p38 MAPK pathway, which often regulates proteins downstream, including potentially C1orf190.

Continuing with the theme of kinase inhibition, SP600125 inhibits JNK, another kinase that can be part of the signaling pathways involving C1orf190. By inhibiting JNK, SP600125 can prevent the activation of C1orf190. Triciribine specifically targets AKT signaling, which is crucial for the phosphorylation state and activity of C1orf190, thus its inhibition can lead to a decrease in C1orf190 activity. Dasatinib, known for its broad-spectrum tyrosine kinase inhibition, can block kinases that phosphorylate C1orf190, thereby inhibiting its function. Leflunomide inhibits dihydroorotate dehydrogenase, and this inhibition can lead to a decrease in C1orf190 activity if pyrimidine synthesis is required for its function. Lastly, bortezomib, a proteasome inhibitor, can prevent the degradation of regulatory proteins that inhibit C1orf190, leading to an upregulation of C1orf190 inhibitory mechanisms. Each of these chemicals can disrupt the specific signaling pathways and biochemical processes that are necessary for the functional activity of C1orf190, thereby leading to its inhibition.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Inhibits CDK4/6 involved in cell cycle progression, which could be essential for C1orf149-related processes.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

Inhibits MEK1/2 in the MAPK pathway, potentially crucial for signaling processes involving C1orf149.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Inhibits PI3K, disrupting downstream signaling that might be necessary for C1orf149 function.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Inhibits Src family kinases, possibly affecting signaling pathways regulating C1orf149 activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

Inhibits MEK1/2, which may disrupt ERK pathway signals involved in C1orf149's functional roles.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

Inhibits p38 MAPK, potentially affecting stress response pathways that involve C1orf149.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Inhibits mTOR, which might be necessary for C1orf149-related processes like growth and proliferation.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, which may be involved in apoptotic and growth pathways related to C1orf149.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple tyrosine kinases, potentially affecting angiogenesis and growth pathways involving C1orf149.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Inhibits receptor tyrosine kinases, which could affect growth factor signaling related to C1orf149.